- Health Canada has approved the CTA for AFTX-201, developed by Affinia Therapeutics, for BAG3-associated dilated cardiomyopathy (DCM)
- AFTX-201 is an investigational AAV-based gene therapy delivering a full-length BAG3 transgene, designed for efficient cardiac targeting at 5–10x lower doses vs conventional capsids
- The therapy will be evaluated in the Phase 1/2 UPBEAT trial, assessing safety, tolerability, and preliminary efficacy following a one-time IV administration
- The program is supported by preclinical data showing restored cardiac function, alongside regulatory momentum with U.S. FDA IND clearance and Fast Track, and EMA Orphan Drug designation
Takeaways:
Health Canada’s CTA clearance positions Affinia among the first wave of next‑gen cardiac gene therapy players, using a bespoke AAV capsid to go after genetically defined BAG3‑DCM at 5–10x lower doses than legacy AAV9/AAVrh74 approaches.
UPBEAT’s launch across the U.S. and Canada, backed by FDA Fast Track and EMA orphan status, de‑risks early development and validates BAG3‑DCM as a commercially meaningful niche, potentially opening a new subsegment in inherited cardiomyopathy gene therapy if early IV, one‑and‑done data translate in humans.
Source: Businesswire
